Morepen Laboratories Ltd

Morepen Laboratories Limited's Q2 and H1 FY27 investor presentation highlights strong financial performance, with two consecutive quarters of record revenue and earnings. Revenue for Q2 FY27 reached Rs. 755 crore, up 273% year-over-year, while EBITDA was Rs. 132 crore, reflecting a 897 basis point increase in EBITDA margin. For H1 FY27, revenue totaled Rs. 1,330 crore, a 57% increase from the prior year, with EBITDA at Rs. 220 crore and a 16.50% margin. PAT grew by 243% year-over-year. The company emphasized its CDMO segment's scale-up, with CDMO revenue contributing over 52% of API and CDMO combined revenue. API revenue saw a 25% share from new molecules, and exports grew by 122% year-over-year, now representing 50% of total sales. The presentation also noted improvements in financial metrics, including ROCE at 18.8% and a debt-to-equity ratio of 0.23. Strategic focus areas include expanding global programs, enhancing innovation through new technologies, and scaling medical devices under a chronic-care franchise. The company highlighted its platform's diversification, compliance, and scalability for long-term growth.

The presentation emphasizes strong revenue and earnings growth, significant improvements in financial metrics, and strategic advancements in CDMO and API segments, reflecting a positive outlook.